Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy
- Evaxion today presents a novel AI model designed to predict patient responses to standard-of-care cancer immunotherapy
- The model demonstrates promising potential for improving patient outcomes, reducing healthcare costs and is scalable for broader applications
- Evaxion will pursue a partnership-based approach towards a commercial offering
COPENHAGEN, Denmark, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, presents for the first time its AI model designed to predict patient responses to cancer immunotherapy at the Biomarkers & Precision Oncology Europe conference in Berlin, Germany.
The broad use of immunotherapy drugs called checkpoint inhibitors has significantly advanced cancer treatment. However, their effectiveness is limited, with success rates at approximately 15% for most cancers. This inherent challenge emphasizes the critical need for a reliable approach to identify the patients who will benefit from standard-of-care cancer immunotherapy. This can improve patient outcomes and reduce healthcare costs.
“When I joined Evaxion, I was inspired by the wealth of opportunities to improve the lives of patients facing life-threatening diseases. Building upon Evaxion’s core competencies, we have developed an AI model that shows promising results in predicting patients at risk of advancing into progressive disease while undergoing checkpoint inhibitor therapy, enabling earlier intervention with alternative treatments,” commented Christian Kanstrup, Evaxion’s Chief Executive Officer.
Christian continued, “We set out to improve patient outcomes and address the growing healthcare burden by developing our first checkpoint inhibitor response predictor model. The model relies on our unique AI-Immunology™ platform, builds upon our existing core competencies and is part of the “Responder” leg of our corporate strategy. Today’s presentation marks our first step on our journey towards this goal, and we will develop a commercial offering where collaboration and partnerships will be instrumental in achieving our vision for a more cost-effective and efficient healthcare system as well as improving patient outcomes.”
Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform: AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties, including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from the worldwide ongoing COVID-19 pandemic and the ongoing conflict in the region surrounding Ukraine and Russia and the Middle East; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Torqx declares offer for Beter Bed Holding unconditional; 95.14% of Shares now tendered or committed29.11.2023 20:15:00 CET | Press release
JOINT PRESS RELEASE This is a joint press release by Beter Bed Holding N.V. ("Beter Bed Holding" or the "Company") and 959 B.V. (the "Offeror"), a company controlled by Torqx Capital Partners ("Torqx"). This joint press release is issued pursuant to the Article 16, paragraphs 1 and 2, Article 17 paragraph 1 and Article 4, paragraph 3 of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft, the "Decree") in connection with the recommended public offer by the Offeror for all the issued and outstanding shares in the capital of the Company (the "Offer"). This press release does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities in the Company. Any offer is only made by means of the offer memorandum (the "Offer Memorandum"), dated 4 October 2023, approved by the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten, the "AFM"). Terms not defined in this press release will have the meaning as set fort
Kvalitena AB (publ) publicerar kvartalsrapport för Q3 202329.11.2023 20:00:00 CET | Pressemelding
Kvalitena publicerar kvartalsrapport för Q3 2023 Bilaga Delårsrapport Q3 2023
Fjárhagsáætlun Sveitarfélagsins Árborgar 2024 og þriggja ára áætlun 2025 – 202729.11.2023 19:50:00 CET | Press release
FjárhagsáætlunSveitarfélagsins Árborgar 2024 og þriggja ára áætlun 2025 – 2027 Fjárhagsáætlun Sveitarfélagsins Árborgar fyrir árið 2024 og þriggja ára áætlun fyrir tímabilið 2025 – 2027 var lögð fram í bæjarstjórn Árborgar til fyrri umræðu í dag. Gert er ráð fyrir að seinni umræða og afgreiðsla fjárhagsáætlunar í bæjarstjórn verði miðvikudaginn 13. desember 2024. Fjárhagsáætlun ársins 2024 gerir ráð fyrir að rekstrarniðurstaða A- og B- hluta verði jákvæð um 30 millj.kr. og EBITDA verði 3,09 ma.kr. Gert er ráð fyrir að í lok árs 2024 nemi eignir samtals 31,4 ma.kr. Gert er ráð fyrir að skuldaviðmið skv. reglugerð 502/2012 lækki niður í 144,0% árið 2024. Útkomuspá fyrir árið 2023 gerir ráð fyrir að skuldaviðmið verði 164,9%. Veltufé frá rekstri er áætlað 2,276 ma.kr árið 2024, 2,697 ma kr. árið 2025, 2,105 ma kr. árið 2026 og 2,367 ma kr. árið 2027. Framlegðarhlutfall er áætlað 16,4% fyrir árið 2024 sem er hækkun um 9,5% frá útkomuspá fyrir árið 2023.Framlegðarhlutfall er áætlað 16,7% fy
Iveco Group N.V. publishes its 2024 Corporate Calendar29.11.2023 18:30:00 CET | Press release
Turin, 29th November 2023. Iveco Group N.V. (EXM: IVG) announces the following corporate calendar dates for 2024: DateEarnings releases9th FebruaryResults for 4th quarter and preliminary annual results 202310th MayResults for 1st quarter 202425th JulyResults for 2nd quarter and 1st half 20247th NovemberResults for 3rd quarter 2024 The Annual General Meeting for the approval of Iveco Group N.V.’s Financial Statements at 31st December 2023 is scheduled to take place in mid April 2024 (*). The 2024 corporate calendar is available on the corporate website: www.ivecogroup.com. (*) In compliance with the requirements set forth by the lnstructions of the Regulation of Borsa Italiana S.p.A., please note that, should the Annual General Meeting resolve a dividend related to the 2023 financial year, the month planned for the dividend detachment (ex-date) would be April. This information is provided for the aforesaid regulatory provisions only and it cannot be interpreted in any way as a forecast
PUBLICATION OF A TRANSPARENCY NOTIFICATION29.11.2023 18:30:00 CET | Press release
Publication on November 29, 2023 at 18:30 CET after market closing Regulated information EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) PUBLICATION OF A TRANSPARENCY NOTIFICATION (Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings) On November 27, 2023, EVS Broadcast Equipment has received a transparency notification indicating that Otus Capital Management Limited now holds 4.99% of the voting rights of the company. Otus Capital Management Limited has therefore crossed down the threshold of 5%. The notification, dated November 27, 2023, contains the following information: Reason for the notification: acquisition or disposal of voting securities or voting rightsNotification by: A parent undertaking or a controlling personPersons subject to the notification requirement: Otus Capital Management Limited, 29 Queen Anne’s Gate, London SW1H 9BU, UK; Andrew GibbsTransaction date: November 24, 2023Threshold that